Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) shares rose 15.8% during mid-day trading on Wednesday . The stock traded as high as $0.46 and last traded at $0.44, approximately 162,100 shares changed hands during trading. A decline of 32% from the average daily volume of 239,714 shares. The stock had previously closed at $0.38.

Separately, HC Wainwright restated a “buy” rating on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a research report on Wednesday, June 5th.

The company has a market capitalization of $46.92 million, a price-to-earnings ratio of -2.44 and a beta of 0.23. The company has a fifty day simple moving average of $0.31 and a two-hundred day simple moving average of $0.38.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04. Equities research analysts forecast that Zomedica Pharmaceuticals Corp will post -0.16 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 1,523.2% during the 2nd quarter. Morgan Stanley now owns 111,598 shares of the company’s stock valued at $25,000 after buying an additional 104,723 shares during the period. Paloma Partners Management Co purchased a new position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the 2nd quarter worth about $45,000. Vanguard Group Inc. raised its holdings in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 139.1% in the 2nd quarter. Vanguard Group Inc. now owns 383,154 shares of the company’s stock worth $88,000 after purchasing an additional 222,920 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock valued at $168,000 after purchasing an additional 16,065 shares in the last quarter. 13.06% of the stock is owned by institutional investors.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile (NYSE:ZOM)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Further Reading: What is the balance sheet?

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.